Research for treatments, prevention and a cure
DEBUG INFO [ON]
Page template: single-clinical-trials.php
Search terms : 

Clinical Trials

  • Clinical Studies

Prevention and Vulnerable Populations (PVP)


CTN 244: STOP HIV & AIDS in IDU

Seek and Treat for Optimal outcomes and Prevention in HIV& AIDS in IDU

Print Friendly, PDF & Email

About the study

This study will expand highly active antiretroviral therapy (HAART) coverage among injection drug users (IDUs) in the Downtown East Side of Vancouver, BC. Over a six-year period, researchers will study if expanded HAART among IDUs will lead to a reduction in the number of new HIV infections and a decrease in adverse HIV/AIDS health outcomes among the target population.

The study seeks to enroll 2000 HIV-infected IDU adults who are medically eligible for antiretroviral therapy (based on current guidelines), but are not accessing therapy or are unaware of their HIV infection status.

About the approach/intervention

In recent years, researchers have expressed growing interest in using HAART to directly prevent HIV transmission. Strong evidence has become available indicating that HAART can impact transmission of HIV. HAART has the ability to effectively render HIV undetectable in blood and genital secretions and this is associated with decreased risk of transmission.

Knowledge gained from this study should assist in the development of a public health policy for the expansion of HAART, as well as enhance the effectiveness of traditional prevention efforts aimed to reduce HIV incidence

Eligibility criteria

Individuals will be eligible for the study if they meet the following inclusion criteria:

Inclusion Criteria

  • All HAART-naïve HIV-positive adult IDUs of BC who are eligible for antiretroviral therapy under the current Treatment Guidelines established by the BC Centre for Excellence in HIV/AIDS.

Participating sites

British Columbia
Dr. Julio Montaner
St. Paul’s Hospital, Vancouver

Dr. Marianne Harris
St. Paul’s Hospital, Vancouver
604-806-8771

Additional Information

If you would like more information on this clinical study, please refer to a participating site.

Principal Investigators

Dr. Marianne Harris and Dr. Julio Montaner

Latest News

Why do we need PrEP Guidelines? Ask an expert. VIDEO

| Uncategorized | No Comments

Despite efforts to reduce new incidences of HIV like condom campaigns, needle exchanges, and treatment as prevention, the actual number…

Call for Nominations: Community Advisory Committee (CAC) 2018

| Uncategorized | No Comments

The CIHR Canadian HIV Trials Network (CTN/Network) is an innovative partnership funded by the Canadian Institutes of Health Research to…

Guest Blog: Dr. Nadine Kronfli on HCV treatment in Canadian prisons

| Hepatitis C | No Comments

Persons in custody in Canadian prisons have a 25-fold higher rate of hepatitis C (HCV) infection than the general population….

Guest Blog: CTN Postdoc Dr. Malika Sharma

| Uncategorized | No Comments

CTN Postdoctoral Fellow Dr. Malika Sharma writes about the current state of PrEP in Canada and how CTN 303 looks to change the way these HIV prevention drugs are delivered.

Research for treatments, prevention and a cure